Literature DB >> 31917459

YAP/TAZ regulates the expression of proteoglycan 4 and tenascin C in superficial-zone chondrocytes.

E Delve, V Co, S C Regmi, J Parreno, T A Schmidt, R A Kandel1.   

Abstract

The roles of cell division control protein 42 homologue (CDC42) and actin polymerisation in regulating the phenotype of superficial-zone chondrocytes (SZCs) have been demonstrated in vitro; however, the signalling pathway(s) downstream have yet to be fully elucidated. The study hypothesis was that Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) act downstream to regulate proteoglycan 4 (PRG4) and tenascin C (TNC). Bovine SZCs grown in monolayer were treated with ML141 (CDC42 inhibitor) or the actin depolymerising agents, latrunculin B and cytochalasin D, to determine the effect on YAP/TAZ. Verteporfin (YAP/TAZ inhibitor) and YAP/TAZ siRNA-mediated knockdown were used to determine their role in regulating PRG4 and TNC. ML141 treatment reduced total YAP/TAZ protein, nuclear TAZ levels and the YAP/TAZ target gene, connective tissue growth factor (CTGF) mRNA levels. Latrunculin B decreased nuclear TAZ, while cytochalasin D treatment trended towards increased nuclear TAZ (p = 0.06), correlating with decreased and increased CTGF mRNA levels, respectively. Verteporfin treatment decreased PRG4 and TNC expression, with no effect on actin polymerisation. siRNA-mediated knockdown of YAP/TAZ revealed that PRG4 was regulated by YAP/TAZ while TNC was regulated by TAZ only. As cytochalasin D can activate myocardin-related transcription factor-A (MRTF-A), siRNA-mediated knockdown was performed to determine the role of MRTF-A in regulating YAP/TAZ. Although nuclear TAZ decreased, no significant changes in total protein levels were observed. Findings suggested that CDC42 and actin polymerisation regulated SZCs through multiple actin-regulated pathways. Understanding the regulation of these chondroprotective molecules may have important implications for prevention/treatment of osteoarthritis.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31917459     DOI: 10.22203/eCM.v039a03

Source DB:  PubMed          Journal:  Eur Cell Mater        ISSN: 1473-2262            Impact factor:   3.942


  8 in total

1.  Primary Cilia Direct Murine Articular Cartilage Tidemark Patterning Through Hedgehog Signaling and Ambulatory Load.

Authors:  Danielle Rux; Kimberly Helbig; Biao Han; Courtney Cortese; Eiki Koyama; Lin Han; Maurizio Pacifici
Journal:  J Bone Miner Res       Date:  2022-02-13       Impact factor: 6.390

Review 2.  The YAP/TAZ Pathway in Osteogenesis and Bone Sarcoma Pathogenesis.

Authors:  Heinrich Kovar; Lisa Bierbaumer; Branka Radic-Sarikas
Journal:  Cells       Date:  2020-04-15       Impact factor: 6.600

Review 3.  Rho GTPase signaling in rheumatic diseases.

Authors:  Ruijie Zeng; Zewei Zhuo; Yujun Luo; Weihong Sha; Hao Chen
Journal:  iScience       Date:  2021-12-14

4.  G protein coupled estrogen receptor attenuates mechanical stress-mediated apoptosis of chondrocyte in osteoarthritis via suppression of Piezo1.

Authors:  Yi Sun; Ping Leng; Pengcheng Guo; Huanshen Gao; Yikai Liu; Chenkai Li; Zhenghui Li; Haining Zhang
Journal:  Mol Med       Date:  2021-08-28       Impact factor: 6.354

5.  Targeting the IGF/PI3K/mTOR pathway and AXL/YAP1/TAZ pathways in primary bone cancer.

Authors:  Danh D Truong; Salah-Eddine Lamhamedi-Cherradi; Joseph A Ludwig
Journal:  J Bone Oncol       Date:  2022-02-24       Impact factor: 4.072

Review 6.  The superficial zone of articular cartilage.

Authors:  Taku Saito
Journal:  Inflamm Regen       Date:  2022-05-02

Review 7.  Roles of Cartilage-Resident Stem/Progenitor Cells in Cartilage Physiology, Development, Repair and Osteoarthritis.

Authors:  Wei Xu; Wei Wang; Da Liu; Dongfa Liao
Journal:  Cells       Date:  2022-07-27       Impact factor: 7.666

8.  17‑AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDA‑MB‑231 breast cancer cells.

Authors:  Yu Zuo; Heng Xu; Zhifeng Chen; Fengmin Xiong; Bei Zhang; Kaixian Chen; Hualiang Jiang; Cheng Luo; Hao Zhang
Journal:  Oncol Rep       Date:  2020-03-26       Impact factor: 3.906

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.